Alentis Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 66

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $181M

  • Investors
  • 21

Alentis Therapeutics General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases. The company develops innovative therapies for the treatment of cancer and other serious diseases, targeting immune checkpoints and modulating the immune system to enhance its ability to fight tumors, enabling medical researchers to treat liver fibrosis, cirrhosis, and liver cancer in patients.

Contact Information

Website
www.alentis.ch
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Swiss Innovation Park
  • Hegenheimermattweg 167A
  • 4123 Allschwil
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Swiss Innovation Park
  • Hegenheimermattweg 167A
  • 4123 Allschwil
  • Switzerland
+41 061

Alentis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alentis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series D) 11-Nov-2024 $181M Completed Clinical Trials - Phase 2
8. Grant 09-May-2023 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 13-Apr-2023 Completed Clinical Trials - Phase 2
6. Accelerator/Incubator 26-Jul-2022 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series C) Cancelled Clinical Trials - Phase 1
4. Early Stage VC (Series B) 15-Jun-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 29-Apr-2019 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2019 Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2019 Completed Pre-Clinical Trials
To view Alentis Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alentis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic dise
Drug Discovery
Allschwil, Switzerland
66 As of 2025

Amsterdam, Netherlands
 

Taipei, Taiwan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alentis Therapeutics Competitors (47)

One of Alentis Therapeutics’s 47 competitors is NorthSea Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NorthSea Therapeutics Venture Capital-Backed Amsterdam, Netherlands
Onward Therapeutics Venture Capital-Backed Taipei, Taiwan
Galectin Therapeutics Corporation Norcross, GA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Verastem Formerly VC-backed Needham, MA
You’re viewing 5 of 47 competitors. Get the full list »

Alentis Therapeutics Patents

Alentis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026057702-A1 Claudin-1/egfr bispecific antibodies Pending 12-Sep-2024
WO-2026057723-A1 Claudin-1/egfr bispecific antibodies for targeted degradation Pending 12-Sep-2024
AU-2025260873-A1 Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof Pending 26-Apr-2024
WO-2025224337-A1 Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof Pending 26-Apr-2024
AU-2025263283-A1 Anti-cldn1 antibody-drug conjugates comprising mmae and methods of use thereof Pending 26-Apr-2024 A61K47/68031
To view Alentis Therapeutics’s complete patent history, request access »

Alentis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alentis Therapeutics Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avego Management PE/Buyout Minority
Catalio Capital Management Venture Capital Minority
Double Bioventures Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
Longitude Capital Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

Alentis Therapeutics FAQs

  • When was Alentis Therapeutics founded?

    Alentis Therapeutics was founded in 2019.

  • Where is Alentis Therapeutics headquartered?

    Alentis Therapeutics is headquartered in Allschwil, Switzerland.

  • What is the size of Alentis Therapeutics?

    Alentis Therapeutics has 66 total employees.

  • What industry is Alentis Therapeutics in?

    Alentis Therapeutics’s primary industry is Drug Discovery.

  • Is Alentis Therapeutics a private or public company?

    Alentis Therapeutics is a Private company.

  • What is Alentis Therapeutics’s current revenue?

    The current revenue for Alentis Therapeutics is .

  • How much funding has Alentis Therapeutics raised over time?

    Alentis Therapeutics has raised $362M.

  • Who are Alentis Therapeutics’s investors?

    Avego Management, Catalio Capital Management, Double Bioventures, Frazier Healthcare Partners, and Longitude Capital are 5 of 21 investors who have invested in Alentis Therapeutics.

  • Who are Alentis Therapeutics’s competitors?

    NorthSea Therapeutics, Onward Therapeutics, Galectin Therapeutics, Sangamo Therapeutics, and Verastem are some of the 47 competitors of Alentis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process